27 results found.

Recurrent Melanoma, or Stage IV Melanoma Clinical Trial using NA17.A2 peptide vaccine; recombinant MAGE-3.1 antigen; recombinant interleukin-12; MART-1 antigen; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Randomized Phase II Study of Multipeptide Vaccination With or Without IL-12, Then Combined With Regulatory T Cell Depletion Using Daclizumab in Patients With Metastatic Melanoma.
NA17.A2 peptide vaccine; recombinant MAGE-3.1 antigen; recombinant interleukin-12; MART-1 antigen; laboratory biomarker analysis

Melanoma (Skin) Clinical Trial using gene expression analysis; polymerase chain reaction; polymorphism analysis; matrix-assisted laser desorption/ionization time of flight mass spectrometry; medical chart review

Case Comprehensive Cancer Center - Recruiting N/A or older.
- Identification of Genomic Lesions Promoting Nodal Metastasis in Malignant Melanoma.
gene expression analysis; polymerase chain reaction; polymorphism analysis; matrix-assisted laser desorption/ionization time of flight mass spectrometry; medical chart review

Recurrent Melanoma, Stage IA Melanoma, Stage IB Melanoma, Stage I Clinical Trial using fluorescein sodium injection; diagnostic microscopy; therapeutic conventional surgery; laboratory biomarker analysis

Roswell Park Cancer Institute - Recruiting 18 years or older.
- A Pilot Study of Feasibility of Performing Intravital Microscopy in Melanoma Patients.
fluorescein sodium injection; diagnostic microscopy; therapeutic conventional surgery; laboratory biomarker analysis

Recurrent Melanoma, Stage IV Melanoma, or Tumors Metastatic to Br Clinical Trial using Ipilimumab; Whole-Brain Radiation Therapy (WBRT); Stereotactic Radiosurgery (SRS)

Thomas Jefferson University - Recruiting 18 years or older.
- Phase I Study of Ipilimumab Combined With Whole Brain Radiation Therapy or Radiosurgery for Melanoma Patients With Brain Metastases.
Ipilimumab; Whole-Brain Radiation Therapy (WBRT); Stereotactic Radiosurgery (SRS)

Melanoma Clinical Trial using Dabrafenib

Memorial Sloan-Kettering Cancer Center - Recruiting 16 years or older.
- A Phase 2 Trial of Adjuvant Dabrafenib (GSK2118436) in Patients With Surgically Resected AJCC Stage IIIC Melanoma Characterized by a BRAFV600E/K Mutation.
Dabrafenib

Recurrent Melanoma, Stage IIIA Melanoma, Stage IIIB Melanoma, Sta Clinical Trial using dabrafenib; ipilimumab; trametinib; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Sequential Safety and Biomarker Study of BRAF-MEK Inhibition on the Immune Response in the Context of CTLA-4 Blockade for BRAF Mutant Melanoma.
dabrafenib; ipilimumab; trametinib; laboratory biomarker analysis

Malignant Melanoma Clinical Trial using Zelboraf (vemurafenib)

Genentech - Recruiting 16 years or older.
- An Open-Label, Multicenter, Phase II Study Of Continuous Oral Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E.
Zelboraf (vemurafenib)

Malignant Melanoma With Metastasis Clinical Trial using Vaccine consisting of a peptide derived from the protein IDO

Herlev Hospital - Recruiting 18 years to 80 years.
- Peptide Vaccination in Combination With Either Ipilimumab or Vemurafenib for the Treatment of Patients With Unresectable Stage III or IV Malignant Melanoma A Phase I Study (First in Man).
Vaccine consisting of a peptide derived from the protein IDO

Melanoma Clinical Trial using A-dmDT390-bisFv(UCHT1); Ionizing Radiation

Angimmune LLC - Recruiting 18 years to 80 years.
- Phase I/II Trial of A-dmDT390-bisFv(UCHT1) Fusion Protein in Combination With Ionizing Radiation for the Treatment of Stage IV Melanoma.
A-dmDT390-bisFv(UCHT1); Ionizing Radiation

Recurrent Melanoma, Stage IIIA Melanoma, Stage IIIB Melanoma, Sta Clinical Trial using cyclophosphamide; fludarabine phosphate; therapeutic tumor infiltrating lymphocytes; aldesleukin; laboratory biomarker analysis

Fred Hutchinson Cancer Research Center - Recruiting 18 years or older.
- Cellular Adoptive Immunotherapy Using Autologous Tumor-Infiltrating Lymphocytes Following Lymphodepletion With Cyclophosphamide and Fludarabine for Patients With Metastatic Melanoma.
cyclophosphamide; fludarabine phosphate; therapeutic tumor infiltrating lymphocytes; aldesleukin; laboratory biomarker analysis

Advanced Melanoma Clinical Trial using paclitaxel albumin-stabilized nanoparticle formulation

Mayo Clinic - Recruiting 18 years or older.
- .
paclitaxel albumin-stabilized nanoparticle formulation

Recurrent Melanoma, Stage IIIA Melanoma, Stage IIIB Melanoma, Sta Clinical Trial using dabrafenib; trametinib; navitoclax; pharmacological study; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- Phase I/II Study of Dabrafenib, Trametinib, and Navitoclax in BRAF Mutant Melanoma and Other Solid Tumors.
dabrafenib; trametinib; navitoclax; pharmacological study; laboratory biomarker analysis

Recurrent Melanoma, Stage IIIB Melanoma, Stage IIIC Melanoma, or Clinical Trial using ipilimumab; recombinant interferon alfa-2b; quality-of-life assessment

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon a-2b for Resected High-Risk Melanoma.
ipilimumab; recombinant interferon alfa-2b; quality-of-life assessment

Male Breast Cancer, Recurrent Melanoma, Stage IV Breast Cancer, S Clinical Trial using propranolol hydrochloride; Correlative Studies

Ohio State University Comprehensive Cancer Center - Recruiting 18 years or older.
- A Pilot Study of Beta-Blockers in Patients With Advanced Cancer.
propranolol hydrochloride; Correlative Studies

Malignant Melanoma Clinical Trial using Ipilimumab

Bristol-Myers Squibb - Recruiting 12 years to 17 years.
- Phase 2 Study of Ipilimumab in Children and Adolescents (12 to < 18 Years) With Previously Treated or Untreated, Unresectable Stage III or Stage IV Malignant Melanoma.
Ipilimumab

Malignant Melanoma Clinical Trial using vemurafenib

Hoffmann-La Roche - Recruiting 12 years to 17 years.
- An Open-label, Multicenter, Single-arm, Phase I Dose-escalation With Efficacy Tail Extension Study of RO5185426 in Pediatric Patients With Surgically Incurable and Unresectable Stage IIIC or Stage IV Melanoma Harboring BRAFV600 Mutations Mutations.
vemurafenib

Malignant Melanoma Clinical Trial using BMS-936558 (MDX1106-04); Ipilimumab

Bristol-Myers Squibb - Recruiting 18 years or older.
- A Phase 1b, Open-label, Multicenter, Multidose, Dose-escalation Study of BMS-936558 (MDX-1106) in Combination With Ipilimumab in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma.
BMS-936558 (MDX1106-04); Ipilimumab

Recurrent Melanoma, Stage IIIB Melanoma, Stage IIIC Melanoma, or Clinical Trial using recombinant hsp110-gp100 chaperone complex vaccine

Roswell Park Cancer Institute - Recruiting 18 years or older.
- A Phase I Trial of a Recombinant Human hsp110-gp100 Chaperone Complex Vaccine for Advanced Stage IIIB/C or IV Melanoma.
recombinant hsp110-gp100 chaperone complex vaccine

Stage IV Melanoma Clinical Trial using paclitaxel albumin-stabilized nanoparticle formulation; bevacizumab; ipilimumab; laboratory biomarker analysis; pharmacological study

Academic and Community Cancer Research United - Recruiting 18 years or older.
- Randomized Phase II Study of AB (AbraxaneT, Bevacizumab) Versus Ipilimumab for 1st Line Therapy of Unresectable Stage IV Metastatic Malignant Melanoma (BRAF V600E Negative).
paclitaxel albumin-stabilized nanoparticle formulation; bevacizumab; ipilimumab; laboratory biomarker analysis; pharmacological study

Melanoma Clinical Trial using XL888; Vemurafenib

H. Lee Moffitt Cancer Center and Research Institute - Recruiting 18 years or older.
- Phase I Study of Escalating Doses of XL888 With Vemurafenib for Patients With Unresectable BRAF Mutated Stage III/IV Melanoma.
XL888; Vemurafenib

Melanoma Clinical Trial using LGX818

Memorial Sloan-Kettering Cancer Center - Recruiting 18 years or older.
- A Phase 2 Trial of the BRAF Inhibitor, LGX818, Utilizing a Pulsatile Schedule in Patients With Stage IV or Unresectable Stage III Melanoma Characterized by a BRAFV600 Mutation.
LGX818

Melanoma (Skin) Clinical Trial using cisplatin; sorafenib tosylate; tamoxifen citrate; adjuvant therapy

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Phase II Pilot Trial of Sorafenib, Tamoxifen and Cisplatin as Adjuvant Therapy for Patients With Stage III Malignant Melanoma.
cisplatin; sorafenib tosylate; tamoxifen citrate; adjuvant therapy

Melanoma, or Skin Cancer Clinical Trial using Panobinostat; Ipilimumab

H. Lee Moffitt Cancer Center and Research Institute - Recruiting 18 years or older.
- A Phase 1 Study of HDAC Inhibitor Panobinostat (LBH 589) Administered in Combination With Ipilimumab in Subjects With Unresectable Stage III or Stage IV Melanoma.
Panobinostat; Ipilimumab

Recurrent Melanoma, Stage IIIA Melanoma, Stage IIIB Melanoma, Sta Clinical Trial using ipilimumab; recombinant interferon alfa-2b; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Randomized Phase II Study of Ipilimumab at 3 mg/kg or 10 mg/kg Alone or in Combination With High Dose Interferon-Alpha in Advanced Melanoma.
ipilimumab; recombinant interferon alfa-2b; laboratory biomarker analysis

Recurrent Melanoma, Stage IIIA Melanoma, Stage IIIB Melanoma, Sta Clinical Trial using riluzole; sorafenib tosylate; diagnostic laboratory biomarker analysis; pharmacological study

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Phase I Trial of Riluzole and Sorafenib in Patients With Advanced Solid Tumors and Melanoma.
riluzole; sorafenib tosylate; diagnostic laboratory biomarker analysis; pharmacological study

Advanced Solid Tumors Clinical Trial using E7050 plus E7080; E7080 plus E7050; E7050 plus E7080 or E7080 alone plus E7050 add-on therapy; E7050

Eisai Inc. - Recruiting N/A or older.
- An Open-Label, Multicenter Phase 1b/2 Study of E7050 in Combination With E7080 in Subjects With Advanced Solid Tumors (Dose Escalation) and in Subjects With Recurrent Glioblastoma or Unresectable Stage III or Stage IV Melanoma After Prior Systemic Therapy (Expansion Cohort and Phase 2).
E7050 plus E7080; E7080 plus E7050; E7050 plus E7080 or E7080 alone plus E7050 add-on therapy; E7050

Malignant Skin Melanoma T0, Stage III Melanoma, Stage IV Melanoma Clinical Trial using Nilotinib

Assistance Publique - H“pitaux de Paris - Recruiting 18 years or older.
- Phase II Multicentric Uncontrolled National Trial Assessing the Efficacy of Nilotinib in First or Second Line Treatment of Primary Melanomas , Stage III Unresectable Melanomas, or Stage IV Melanomas With c-KIT Mutation or Amplification..
Nilotinib